Age-Related Macular Degeneration Market

Market Overview: 

The 7 major age-related macular degeneration markets reached a value of US$ 10.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 12.0 Billion by 2034, exhibiting a growth rate (CAGR) of 1.54% during 2024-2034.

The age-related macular degeneration market has been comprehensively analyzed in IMARC's new report titled "Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Age-related macular degeneration (AMD) refers to an acquired eye disease that primarily affects older adults. The illness specifically damages the macula, which is the central part of the retina responsible for sharp and central vision. There are two main types of this ailment: dry and wet. Dry AMD progresses slowly and may result in mild to moderate vision loss, whereas wet AMD can cause sudden and severe central vision impairment. Individuals suffering from the disease may experience difficulty recognizing faces, problems with reading, blurred or distorted central vision, dark or empty areas in the center of the visual field, etc. The diagnosis of this condition typically requires a review of the patient's medical history, underlying symptoms, and ophthalmic examination. During a dilated eye exam, the healthcare provider will examine the macula to check for any abnormalities, such as drusen (yellow deposits) and pigment changes, which are indicative of AMD. Numerous other diagnostic procedures, including optical coherence tomography and indocyanine green angiography, are also utilized to confirm a diagnosis among patients. 

The expanding geriatric population, who are prone to the degradation of macula cells due to structural and blood flow changes, is primarily driving the age-related macular degeneration market. Additionally, the increasing prevalence of several associated risk factors, such as genetic predisposition, high blood pressure, smoking, prolonged exposure to blue light, obesity, consumption of a diet rich in saturated fat, etc., is also propelling the market growth. Moreover, the widespread demand for vascular endothelial growth factor inhibitors, which are injected directly into the eye to reduce abnormal blood vessels, is further creating a positive outlook for the market. Besides this, the escalating adoption of laser photocoagulation for treating AMD, since it helps to alleviate the symptoms and slow down the progression of the ailment in patients, is also acting as another significant growth-inducing factor. Additionally, the rising utilization of retinal gene therapy, owing to its various advantages, including long-lasting effects, reduced treatment frequency, and enhanced quality of life for individuals suffering from this condition, is expected to drive the age-related macular degeneration market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the age-related macular degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for age-related macular degeneration and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the age-related macular degeneration market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the age-related macular degeneration market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the age-related macular degeneration market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current age-related macular degeneration marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the age-related macular degeneration market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the age-related macular degeneration market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the age-related macular degeneration market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of age-related macular degeneration across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of age-related macular degeneration by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of age-related macular degeneration by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of age-related macular degeneration by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with age-related macular degeneration across the seven major markets?
• What is the size of the age-related macular degeneration patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of age-related macular degeneration?
• What will be the growth rate of patients across the seven major markets?
   

Age-Related Macular Degeneration: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for age-related macular degeneration drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the age-related macular degeneration market?
• What are the key regulatory events related to the age-related macular degeneration market?
• What is the structure of clinical trial landscape by status related to the age-related macular degeneration market?
• What is the structure of clinical trial landscape by phase related to the age-related macular degeneration market?
• What is the structure of clinical trial landscape by route of administration related to the age-related macular degeneration market?